A survey of U.S. adults has found that a majority believe that HIV vaccines are the best hope for controlling the global AIDS epidemic and are confident such vaccines can be made. But while most of those surveyed felt it personally important to help support HIV vaccine research, a majority expressed reluctance to support a friend or family member’s participation in an HIV vaccine clinical trial.
These were among the conflicting findings of a telephone survey of more than 3,500 adults to assess attitudes, knowledge and awareness of HIV vaccine research in the United States. The survey, conducted by members of the HIV Vaccine Communications Campaign of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, points to the ongoing challenges HIV vaccine researchers face. A paper on the survey results is available online now and will be published in an upcoming print issue of the Journal of Acquired Immune Deficiency Syndromes.
"Tens of thousands of volunteers are required for the more than 30 HIV vaccine clinical trials currently planned or under way," says NIAID director Anthony S. Fauci, M.D. "It is essential that current and future trials involve volunteers from diverse communities to enable us to find a vaccine that works for all populations."
The NIAID team also assessed trust in the U.S. government’s ability to protect HIV vaccine trial volunteers. While about half of three groups--men who have sex with men (50 percent), African Americans (55 percent) and the general population (57 percent)--said they could trust the government to protect HIV vaccine trial volunteers, the rate of trust among Hispanics was significantly higher at 78 percent.
Based on interviews, focus groups and media analysis, NIAID team members first developed five key messages on vaccine research. They then designed the survey to determine whether these key messages were the most important ones for the HIV Vaccine Communications Campaign to address. These key messages were:
The results of the survey, says Mr. Murguía, have helped identify which populations researchers need to target for better understanding of HIV vaccine research, as well as which messages need to be tailored to specific populations. The NIAID team will work to lower the barriers that inhibit potential volunteers from diverse populations from participating in HIV vaccine trials and to increase community support for those who volunteer for a trial.
NIAID is a component of the National Institutes of Health, an agency of the U.S. Department of Health and Human Services. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on transplantation and immune-related illnesses, including autoimmune disorders, asthma and allergies.
Linda Joy | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...
The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...
At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.
When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...
At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.
Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...
16.03.2018 | Event News
13.03.2018 | Event News
08.03.2018 | Event News
16.03.2018 | Earth Sciences
16.03.2018 | Physics and Astronomy
16.03.2018 | Life Sciences